Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mustafa Asim Demirkol has a total of 89 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Clinical characteristics and mortality risk factors in COVID-19 patients with pulmonary embolism

    by Aysun Şengül, Yusuf Aydemir, Derya Kızılgöz Özaydın, Pınar Akın Kabalak, Yasemin Söyler, Hüsnü Baykal, Muzaffer Onur Turan, Ersin Alkılınç, Fulsen Bozkuş, Pınar Yıldız Gülhan, et al.

    Aims: To evaluate the clinical characteristics, radiological findings, and mortality-related factors in patients with COVID-19-associated pulmonary embolism (PE). Methods: This multicenter retrospective cohort study analyzed data from 13 tertiary centers and included adult patients with molecularly confirmed SARS-CoV-2 infection and radiologically verified PE. Results: A total of 112 patients were included (mean age: 59.9±14.1 years), of whom 50% had severe pneumonia. PE and COVID-19 were diagnosed simultaneously in 29.5% of cases. The median interval between COVID-19 diagnosis and PE development was 6 days. Despite standard or intermediate-dose thromboprophylaxis, PE occurred in 42.9% of patients. Computed tomography pulmonary angiography demonstrated predominantly peripheral embolic involvement (58.0%). According to early mortality risk stratification, 5.4% of patients were classified as high risk and 19.6% as intermediate-high risk. The in-hospital and 30-day mortality rates were 7.1% and 12.5%, respectively. Mortality was significantly associated with advanced age, comorbidities, severe pneumonia, thrombocytopenia, elevated lactate dehydrogenase and ferritin levels, high/intermediate-high risk classification, intensive care unit admission, and invasive mechanical ventilation. Multivariate logistic regression identified thrombocytopenia as an independent predictor of 30-day mortality (OR 10.11, 95% CI 1.49-68.92; p=0.01). Conclusion: PE commonly develops during the early phase of COVID-19 and may occur despite thromboprophylaxis. Early recognition and individualized, risk-adapted anticoagulation strategies are essential.

  • Is local anaesthetic drug allergy really common? A 10-year single-centre retrospective analysis

    by Nihal Yıldırım, Mustafa Asım Demirkol, Zeynep Yegin Katran, İsMet Bulut

    Background: True allergic reactions to local anaesthetic (LA) agents are extremely rare, yet patients are frequently referred to allergy clinics with a history suggestive of LA hypersensitivity. This study aimed to evaluate the clinical characteristics, risk factors, and diagnostic outcomes of patients referred with suspected LA hypersensitivity. Methods: We retrospectively reviewed all patients evaluated for suspected LA hypersensitivity between 2014 and 2025 in a tertiary allergy centre. Demographic, clinical and laboratory data, including comorbid allergic diseases, total IgE, eosinophil count and serum tryptase levels, were analysed. All patients underwent standardised skin testing and, when indicated, subcutaneous provocation testing with preservative-free LA agents. Logistic regression was used to identify independent predictors of LA hypersensitivity history. Results: A total of 149 patients (mean age 46.7 ± 13.9 years; 83.9% females) were included. No confirmed cases of IgE-mediated LA hypersensitivity were detected. The most common comorbidities were atopy (50.0%), asthma (24.3%) and allergic rhinitis (34.4%). True LA hypersensitivity was not confirmed in any case; however, at least one safe agent was identified in 83.2% of patients, most frequently lidocaine (63.8%). In multivariate analysis, age was the only independent predictor of reporting LA hypersensitivity (Odds ratio (OR) = 1.02; P = 0.039). Atopy (OR = 0.36; P < 0.001) and asthma (OR = 0.28; P < 0.001) were found to be negative predictors, possibly reflecting referral bias. Multiple drug hypersensitivity was observed in 1.4% of patients, but was not an independent risk factor. Conclusions: True local anaesthetic hypersensitivity is exceedingly rare. A detailed history combined with appropriate skin and provocation testing prevents unnecessary avoidance of safe agents. Referral bias and overestimation of risk remain common in clinical practice.

  • Open Access

    A Retrospective Look at Early COVID-19 Treatment and Outcomes in Two Tertiary Centers in Türkiye and Bosnia & Herzegovina

    by Rahima Jahic, Mustafa Asim Demirkol, Sefika Umihanic, Jasmina Smajic, Sekib Umihanic, Alma Trnacevic, Amra Adrovic Yildiz, Kamber Kasali, Ayhan Olcay, Nejra Selak, et al.

    During the early months of the COVID-19 pandemic, treatment protocols varied substantially among countries and even between hospitals. This study compared the clinical characteristics, management strategies, and outcomes of hospitalized COVID-19 patients treated in tertiary centers in Türkiye and Bosnia and Herzegovina. We retrospectively analyzed 1338 adults hospitalized with laboratory-confirmed SARS-CoV-2 infection: 657 patients in Tuzla (Bosnia and Herzegovina, June–December 2020) and 681 in İstanbul (Turkiye, April–May 2020). Demographic, clinical, and laboratory data, treatment details (including favipiravir use), need for invasive or non-invasive mechanical ventilation, and in-hospital mortality were extracted from medical records. Patients in Bosnia and Herzegovina were older (61.6 ± 14.4 vs. 56.9 ± 15.8 years; p < 0.001) and had longer hospital stays (9.0 ± 5.5 vs. 7.7 ± 6.1 days; p < 0.001). In the Bosnian cohort, leukocyte, neutrophil, platelet, ferritin, CRP, troponin, creatinine, AST, and ALT levels were significantly higher, whereas hemoglobin and D-dimer levels were lower. The need for ventilatory support was greater in Bosnia and Herzegovina (15.1% vs. 12.2%, p < 0.001), and overall mortality was higher (25.7% vs. 9.3%, p < 0.001). No mortality difference was observed between patients treated and not treated with favipiravir. Despite similar inclusion criteria, patients in Bosnia and Herzegovina exhibited more severe disease, greater organ involvement, and higher mortality than those in Turkiye. Favipiravir use did not influence survival. Inter-country comparisons highlight how differing patient profiles and treatment protocols may impact COVID-19 outcomes; however, interpretation should consider that the two centers contributed data from different phases of the 2020 pandemic, and that country-level differences in circulating variants, healthcare capacity, hospital strain, and evolving clinical guidelines may also have influenced the observed patterns.

  • Open Access

    A rare case of type IV hypersensitivity: Prilocaine allergy

    by Özge Argın, Mustafa Asım Demirkol, Yunus Bozkurt, Nihal Yıldırım, Zeynep Yegin Katran, İsMet Bulut

    Allergic reactions caused by local anesthetics are quite rare and these reactions often manifest as Type I (immediate-type) hypersensitivity; however, Type IV (delayed-type) hypersensitivity reactions also hold clinical significance. Type IV reactions are generally T-lymphocyte mediated and symptoms appear hours or days after antigen exposure. In this case report, a rare Type IV hypersensitivity reaction to prilocaine, an amide-type local anesthetic, is described. The patient presented to our center due to the delayed-onset skin lesions that developed after previous surgical procedures and was evaluated through comprehensive allergy testing. A positive delayed-type reaction to prilocaine was observed in the intradermal and patch tests; however, no reaction was detected in the provocation test performed with mepivacaine. This highlights the importance of careful selection of local anesthetics and consideration of Type IV hypersensitivity. Sharing such cases contributes to increased clinical awareness.

  • Open Access

    Organizing pneumonia following ocrelizumab use in a patient with multiple sclerosis: A case report

    by Nurten Aysan, Gizem Köybaşı, Celal Satıcı, Mustafa Asım Demirkol, Burcu Arpınar Yiğitbaş, Ayşe Filiz Arpaçağ Koşar

    Ocrelizumab is an anti-CD20 monoclonal antibody used in the treatment of primary progressive and relapsing multiple sclerosis (MS). Although cases of organizing pneumonia have been reported in association with other antiCD20 agents such as rituximab, there is insufficient data in the literature on Ocrelizumab-associated lung involvement. Herein, we present a case of organizing pneumonia in a 37-year-old female patient with multiple sclerosis following Ocrelizumab use.


  • Characteristics of our hypoxemic COVID-19 pneumonia patients receiving corticosteroids and mortality-associated factors

    by Aysun Şengül, Pınar Mutlu, Özer Özdemir, Celal Satıcı, Muzaffer Onur Turan, Sertaç Arslan, Nalan Ogan, Zuhal Ekici Ünsal, Fulsen Bozkuş, Aylin Çapraz, et al.

    COVID-19 is a disease associated with diffuse lung injury that has no proven effective treatment yet. It is thought that glucocorticoids may reduce inflammation-mediated lung injury, disease progression, and mortality. We aimed to evaluate our patient’s characteristics and treatment outcomes who received corticosteroids for COVID-19 pneumonia. We conducted a multicenter retrospective study and reviewed 517 patients admitted due to COVID-19 pneumonia who were hypoxemic and administered steroids regarding demographic, laboratory, and radiological characteristics, treatment response, and mortality-associated factors. Of our 517 patients with COVID-19 pneumonia who were hypoxemic and received corticosteroids, the mortality rate was 24.4% (n = 126). The evaluation of mortality-associated factors revealed that age, comorbidities, a CURB-65 score of ≥ 2, higher SOFA scores, presence of MAS, high doses of steroids, type of steroids, COVID-19 treatment, stay in the intensive care unit, high levels of d-dimer, CRP, ferritin, and troponin, and renal dysfunction were associated with mortality. Due to high starting and average steroid doses are more associated with mortality, high-dose steroid administration should be avoided. We believe that knowing the factors associated with mortality in these cases is essential for close follow-up. The use of CURB-65 and SOFA scores can predict prognosis in COVID-19 pneumonia.


  • Area under flow-volume loop may predict severe exacerbation in COPD patients with high grade of dyspnea

    by Celal Satici, Mustafa Asim Demirkol, Burcu Arpinar Yigitbas, Aysegül Erinc, Ayse Filiz Kosar


  • Open Access

    Comparison of demographic and clinical characteristics of hospitalized COVID‐19 patients with severe/critical illness in the first wave versus the second wave

    by Elif Sargin Altunok, Celal Satici, Veysel Dinc, Sadettin Kamat, Mustafa Alkan, Mustafa Asim Demirkol, Ilkim Deniz Toprak, Muhammed Emin Kostek, Semih Yazla, Sinem Nihal Esatoglu

    Due to current advances and growing experience in the management of coronavirus Disease 2019 (COVID‐19), the outcome of COVID‐19 patients with severe/critical illness would be expected to be better in the second wave compared with the first wave. As our hospitalization criteria changed in the second wave, we aimed to investigate whether a favorable outcome occurred in hospitalized COVID‐19 patients with only severe/critical illness. Among 642 laboratory‐confirmed hospitalized COVID‐19 patients in the first wave and 1121 in the second wave, those who met World Health Organization (WHO) definitions for severe or critical illness on admission or during follow‐up were surveyed. Data on demographics, comorbidities, C‐reactive protein (CRP) levels on admission, and outcomes were obtained from an electronic hospital database. Univariate analysis was performed to compare the characteristics of patients in the first and second waves. There were 228 (35.5%) patients with severe/critical illness in the first wave and 681 (60.7%) in the second wave. Both groups were similar in terms of age, gender, and comorbidities, other than chronic kidney disease. Median serum CRP levels were significantly higher in patients in the second wave compared with those in the first wave [109 mg/L (interquartile range [IQR]: 65–157) vs. 87 mg/L (IQR: 39–140); p < 0.001]. However, intensive care unit admission and mortality rates were similar among the waves. Even though a lower mortality rate in the second wave has been reported in previous studies, including all hospitalized COVID‐19 patients, we found similar demographics and outcomes among hospitalized COVID‐19 patients with severe/critical illness in the first and second wave.


  • Open Access

    Cytokine storm in severe COVID‐19 pneumonia

    by Bengül Gürsoy, Cemile D. Sürmeli, Mustafa Alkan, Celal Satıcı, Elif Sargın Altunok, Sadettin Kamat, Berna Demirok, Mustafa A. Demirkol, Akaberk Börü

    In this study, laboratorial parameters of hospitalized novel coronavirus (COVID‐19) patients, who were complicated with severe pneumonia, were compared with the findings of cytokine storm developing in macrophage activation syndrome (MAS)/secondary hemophagocytic lymphohistiocytosis (sHLH). Severe pneumonia occurred as a result of cytokine storm in some patients who needed intensive care unit (ICU), and it is aimed to determine the precursive parameters in this situation. Also in this study, the aim is to identify laboratory criteria that predict worsening disease and ICU intensification, as well as the development of cytokine storm. This article comprises a retrospective cohort study of patients admitted to a single institution with COVID‐19 pneumonia. This study includes 150 confirmed COVID‐19 patients with severe pneumonia. When they were considered as severe pneumonia patients, the clinic and laboratory parameters of this group are compared with H‐score criteria. Patients are divided into two subgroups; patients with worsened symptoms who were transferred into tertiary ICU, and patients with stable symptoms followed in the clinic. For the patients with confirmed COVID‐19 infection, after they become complicated with severe pneumonia, lymphocytopenia (55.3%), anemia (12.0%), thrombocytopenia (19.3%), hyperferritinemia (72.5%), hyperfibrinogenemia (63.7%) and elevated lactate dehydrogenase (LDH) (90.8%), aspartate aminotransaminase (AST) (31.3%), alanine aminotransaminase (ALT) (20.7%) are detected. There were no significant changes in other parameters. Blood parameters between the pre‐ICU period and the ICU period (in which their situation had been worsened and acute respiratory distress syndrome [ARDS] was developed) were also compared. In the latter group lymphocyte levels were found significantly reduced (p = 0.01), and LDH, highly sensitive troponin (hs‐troponin), procalcitonin, and triglyceride levels were significantly increased (p < 0.05). In addition, there was no change in hemoglobin, leukocyte, platelet, ferritin, and liver function test levels, including patients who developed ARDS, similar to the cytokine storm developed in MAS/sHLH. COVID‐19 pneumonia has similar findings as hyperinflammatory syndromes but does not seem to have typical features as in cytokine storm developed in MAS/sHLH. In the severe patient group who has started to develop ARDS signs, a decrease in lymphocyte level in addition to the elevated LDH, hs‐troponin, procalcitonin, and triglyceride levels can be a predictor in progression to ICU admission and could help in the planning of anti‐cytokine therapy.


  • Clinical characteristics of adult patients hospitalized with laboratory-confirmed COVID-19 pneumonia

    by Elif Sargin Altunok, Mustafa Alkan, Sadettin Kamat, Berna Demirok, Celal Satici, Mustafa Asim Demirkol, Bengul Gursoy, Cemile Dilsah Surmeli, Ferhat Cengel, Mustafa Calik, et al.